<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Ajanta Pharma has submitted its annual initial disclosure to BSE and NSE as required by SEBI's November 2018 circular on debt fundraising by large corporates. The company has reported nil outstanding borrowings as of 31st March 2026 and confirmed it does not qualify as a 'Large Corporate' under the criteria. Its highest credit rating during the previous financial year was CARE A1+, issued by CARE Ratings Limited. The company has designated NSE as the stock exchange where any shortfall-related fine would be paid, though this is not applicable given its nil borrowings.
This is a routine regulatory filing with no material impact on shareholders or the stock. The nil borrowings confirm Ajanta Pharma has a debt-free balance sheet, and the CARE A1+ rating reflects strong short-term creditworthiness.